August 20, 2025The Brown University Child and Adolescent Behavior Letter

Preventing HIV with injectable lenacapavir: WHO recommendation

View Full Paper

Ask AI

Bookmark

Introducing lenacapavir as a preventive measure could significantly improve HIV protection efforts globally.
WHO’s recommendation emphasizes the potential of lenacapavir to enhance existing PrEP options for at-risk populations.
The guidelines were publicly announced during the IAS 2025 conference in Kigali, highlighting their importance in HIV prevention.
This landmark policy could reshape global strategies to combat HIV, enhancing accessibility to preventive care.

Implication

New WHO guidelines endorse injectable lenacapavir as a biannual PrEP option for HIV, suggesting possible shifts in global prevention strategies.

Abstract

The World Health Organization (WHO) released new guidelines in July recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre‐exposure prophylaxis (PrEP) option for HIV prevention. The landmark policy could help reshape the global HIV response, according to WHO. The guidelines were issued at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alison Knopf (2025) studied this question.

synapsesocial.com/papers/68af4ce5ad7bf08b1ead6b48 https://doi.org/10.1002/cbl.30898

View Full Paper

Ask AI

Bookmark

Implication

New WHO guidelines endorse injectable lenacapavir as a biannual PrEP option for HIV, suggesting possible shifts in global prevention strategies.

Preventing HIV with injectable lenacapavir: WHO recommendation

Key Points

Implication

Abstract

Discussion

Cite This Study

Preventing HIV with injectable lenacapavir: WHO recommendation

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading